This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Juno Therapeutics Inc.

Drug Names(s): JCAR-015

Description: JCAR015 is an autologous cell product using chimeric antigen receptor (CAR) modified T cells. JCAR-015 cells express the 19-28z CAR, which binds the CD19 antigen and contains a CD28 costimulatory domain.

JCAR015 utilizes CD3 enriched peripheral blood mononuclear cells.

Deal Structure: Juno and Celgene
In June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.

For Juno-originated programs co-developed under the collaboration: